NovoCure (NVCR) 2024 Wells Fargo Healthcare Conference summary

Leadership transition and organizational updates

• CEO transition planned for year-end, with current CFO Ashley Cordova set to take over after extensive succession planning and expanded responsibilities.

• Several key leadership roles have recently transitioned, including HR, CMO, and COO, with strong internal and external candidates filling positions.

• The company’s operational center of gravity has shifted to Switzerland, aligning leadership and research functions geographically.

• The CFO role will be filled externally, as internal candidates did not meet all requirements.

• Executive Chairman will remain active to ensure continuity and leverage institutional knowledge.

Product pipeline and regulatory milestones

• U.S. and European approvals for LUNAR in second-line non-small cell lung cancer are expected by year-end, with launches planned in the U.S. and Germany upon approval.

• No changes to expectations for a broad label or launch timing; reimbursement processes will begin post-approval in key markets.

• METIS filing for brain metastases remains on track for the U.S., Europe, and Japan by year-end, with FDA review under CDRH.

• PANOVA phase 3 trial in first-line locally advanced pancreatic cancer is fully recruited, with top-line results expected in Q4 after data cleanup.

• LUNAR-2 phase 3 trial in first-line lung cancer is enrolling, with a multi-year timeline and a large patient cohort.

Market opportunity and commercial strategy

• LUNAR’s target addressable market (TAM) in the U.S. is estimated at 30,000 on-label patients in second/third-line non-small cell lung cancer, a multiple of the GBM market.

• METIS TAM for brain metastases is estimated at 16,000, with significant overlap and commercial synergies with existing CNS and thoracic sales teams.

• PANOVA’s TAM in the U.S. is 15,000–20,000 for locally advanced pancreatic cancer, about twice the size of the GBM market.

• Early launch focus for new indications will be on building positive clinician experiences before broadening penetration.

• Reimbursement strategies differ by market, with immediate billing possible in the U.S. and Germany, but delayed launches in single-payer markets like France and Japan.